Nathan Hukill resigns from AFT’S Board

AFT Pharmaceuticals Limited, Level 1, 129 Hurstmere Road, Takapuna, Auckland 0622, New Zealand
Incorporated in New Zealand ARBN:
ARBN 609 017 969 investor.relations@aftpharm.com





Market and media release 22 June 2020
Nathan Hukill resigns from AFT’S Board
AFT Pharmaceuticals (NZX; AFT, ASX; AFP) today announces Nathan Hukill, president
of the company’s former major shareholder CRG, has resigned as a non-executive
director of AFT.
The move follows AFT’s $74 million capital restructure
1
, which has seen CRG, a
specialist healthcare investor, sell the 16 million shares it held in the company. CRG
sold its stake because its fund that made the investment is now returning capital to
investors. CRG also provided debt facilities to AFT which were refinanced earlier this
year.
AFT Pharmaceuticals Limited Managing Director Dr Hartley Atkinson said: “Nate and
CRG have played a pivotal role in driving the transformation of AFT. When CRG first
provided finance to and invested in AFT in 2014 we were a small privately-owned
pharma company almost totally focussed on Australasia.

“Since then, with CRG’s assistance, AFT has grown to become an NZX and ASX-listed
company with global aspirations, annual sales exceeding $100 million and a market
capitalisation of circa $420 million.

“The AFT board is very grateful for the support CRG and Nate have provided through
this period. We thank them on behalf of all shareholders and wish them well for the
future.”

Mr Hukill’s resignation is effective immediately and AFT will consider the appointment
of a replacement in the coming months.
For and on behalf of AFT Pharmaceuticals Limited by Malcolm Tubby, Chief Financial
Officer.

For more information:
Investors Media
Dr Hartley Atkinson Richard Inder
Managing Director The Project
AFT Pharmaceuticals Tel: +64 21 645 643
Tel: +64 9488 0232

1
Details of the capital restructure were announced to the NZX on 10 June 2020 (CLICK HERE)

AFT Pharmaceuticals Limited, Level 1, 129 Hurstmere Road, Takapuna, Auckland 0622, New Zealand
Incorporated in New Zealand ARBN:
ARBN 609 017 969 investor.relations@aftpharm.com


About AFT Pharmaceuticals
AFT is a growing multinational pharmaceutical company that develops, markets and
distributes a broad portfolio of pharmaceutical products across a wide range of
therapeutic categories which are distributed across all major pharmaceutical
distribution channels: over-the-counter (OTC), prescription and hospital. Our product
portfolio comprises both proprietary and in-licensed products, and includes patented,
branded and generic drugs. Our business model is to develop and in-license products
for sale by our own dedicated sales teams in our home markets of Australia and New
Zealand and in certain Southeast Asian markets, and to out-license our products to
local licensees and distributors to over 125 countries around the world. For more
information about the company, visit our website www.aftpharm.com
.